WAYNE, N.J., Jan. 4 /PRNewswire/ -- Berlex, Inc. announced today that the company has been awarded a new contract by Premier, Inc., to provide contrast media for Magnetic Resonance Imaging (MRI) to members of the Premier network.
Premier, Inc., is a strategic healthcare alliance entirely owned by more than 200 of the nation’s leading hospital and healthcare systems. These systems operate or are affiliated with nearly 1,700 hospital facilities and hundreds of other healthcare sites throughout the U.S.
“We are pleased to continue our ten-year relationship with Berlex. The decision to provide Magnevist to our membership is a reflection of our committee’s continued support of the product, " said Mike Georgulis, Premier Inc.'s vice president, Sourcing. “The new contract reinforces the value we see in Berlex’s commitment to our members and the communities and patients that our membership serve.”
The new contract extends the longstanding relationship between the two companies. Under the terms of the agreement, Berlex will provide Premier members access to Magnevist(R) (gadopentetate dimeglumine) Injection, the leading contrast media for enhanced MRI.
“We value our long-standing association with Premier, and the award of a new contract demonstrates the outstanding customer service our sales force provides to the Premier membership and their patient community,” said Doug Stefanelli, vice president and general manager, Diagnostic Imaging, Berlex.
ABOUT MAGNEVIST
Magnevist is the leading MRI contrast agent with the broadest range of adult and pediatric clinical indications. Magnevist was invented by a small group of researchers at Berlex’s parent company in Germany. The product received FDA approval in 1988, and extended the power of magnetic resonance imaging (MRI) to help diagnose disease. Since its introduction, Magnevist has been used in over 70 million procedures worldwide and continues to be the most studied MR contrast agent on the market.
As with other contrast media, the possibility of serious or life- threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered. As with other paramagnetic contrast agents, caution should be exercised in patients with renal insufficiency, especially at higher doses. As with other injectable products, cases of phlebitis and thrombophlebitis have been reported; assessment of the dosed limb for the development of injection site reactions is recommended.
Safety and efficacy in children under the age of 2 years have not been established.
About Berlex
Berlex is committed to addressing unmet medical needs through research and development in the areas of oncology, gastroenterology, women’s health, diagnostics and neurology. Berlex also markets diagnostic imaging agents, innovative treatments in the areas of female health care and oncology, as well as specialized therapeutics for life-threatening and disabling diseases of the central nervous system and cardiovascular system. Berlex has business operations in New Jersey, California and Washington. For more information, please visit www.berlex.com.
BERLEX SAFE HARBOR STATEMENT
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Berlex’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Berlex, Inc. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Berlex, Inc.
CONTACT: Heather Levis, Public Relations, Berlex Inc., +1-973-305-5313, orHeather_levis@berlex.com; or Joanne Marion, Investor Relations, ScheringBerlin, Inc., +1-973-487-2164, or joanne_marion@berlex.com
Web site: http://www.berlex.com/
